Consider the systemic perspective. There are problems where we have no idea what's going on. (The pool of possibilities is so big, relative to the budget, that it's practically infinite.)
In these cases, lots of low-N studies could be better than a few high-N ones. It's a balance between the odds of your study giving a false result against the odds of picking the wrong hypothesis.
You mean low observations/ data point?
It's really simple in the medical world.
Money.
Longitudinal data mean following people over years.
Imagine how much money we have to pay these people for 100 people and say for just 5 years.
Medical data/ experiment isn't cheap.
You can do it with rats but it doesn't represent human. And iirc FDA found only 50% of what happen to rats can be replicated to Human when they look at the drug result.
They have Assays now but I'm not sure how well it represent real subject.
The ways FDA does it at least for NTCR is we test for liver toxicology to make things cheaper using assays data. Instead of real human being.
The solution to this is a publication process where you register studies before you do them, in exchange for guaranteed publication once you're done with them. Different fields are further along in establishing such processes. (I've never worked in an empirical field myself, just reporting what I hear from a psychologist friend.)